These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 30318110)

  • 1. Metastatic neuroendocrine tumors of the gastrointestinal tract and pancreas: A surgeon's plea to centering attention on the liver.
    Keutgen XM; Schadde E; Pommier RF; Halfdanarson TR; Howe JR; Kebebew E
    Semin Oncol; 2018 Aug; 45(4):232-235. PubMed ID: 30318110
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors.
    Phan AT; Kunz PL; Reidy-Lagunes DL
    Clin Adv Hematol Oncol; 2015 May; 13(5 Suppl 5):1-18; quiz 1 p following 18. PubMed ID: 26430956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aggressive Locoregional Treatment Improves the Outcome of Liver Metastases from Grade 3 Gastroenteropancreatic Neuroendocrine Tumors.
    Du S; Ni J; Weng L; Ma F; Li S; Wang W; Sang X; Lu X; Zhong S; Mao Y
    Medicine (Baltimore); 2015 Aug; 94(34):e1429. PubMed ID: 26313798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Gastroenteropancreatic Neuroendocrine Tumors.
    Perez K; Chan J
    Surg Pathol Clin; 2019 Dec; 12(4):1045-1053. PubMed ID: 31672293
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Strategies for Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract.
    Cives M; Strosberg J
    Curr Treat Options Oncol; 2017 Mar; 18(3):14. PubMed ID: 28286921
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Treatment of Advanced Gastroenteropancreatic Neuroendocrine Tumors in Korea: Literature Review and Expert Opinion.
    Yoo C; Oh CR; Kim ST; Bae WK; Choi HJ; Oh DY; Lee MA; Ryoo BY
    Cancer Res Treat; 2021 Apr; 53(2):291-300. PubMed ID: 33421978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emerging role of targeted therapies for advanced well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Cloyd JM; Konda B; Shah MH; Pawlik TM
    Expert Rev Clin Pharmacol; 2019 Feb; 12(2):101-108. PubMed ID: 30582383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating Regulatory T Cells: A Novel Marker Associated with Liver Metastasis and the Treatment Response of Transarterial Embolization in Gastroenteropancreatic Neuroendocrine Tumors.
    Liu M; Yu H; Chen L; Yang D; Liu H; Ouyang J; Zhang J; Yan X; Luo Y; Lin Y; He Q; Chen M; Zhang N; Wang Y
    Neuroendocrinology; 2024; 114(9):827-839. PubMed ID: 38061350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update in the management of gastroenteropancreatic neuroendocrine tumors.
    Sedlack AJH; Varghese DG; Naimian A; Yazdian Anari P; Bodei L; Hallet J; Riechelmann RP; Halfdanarson T; Capdevilla J; Del Rivero J
    Cancer; 2024 Sep; 130(18):3090-3105. PubMed ID: 39012928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gastroenteropancreatic Neuroendocrine Tumors.
    Cives M; Strosberg JR
    CA Cancer J Clin; 2018 Nov; 68(6):471-487. PubMed ID: 30295930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors Predicting Prognosis in Metastatic Grade 1 Gastro-entero-pancreatic Neuroendocrine Tumors.
    Pandrowala SA; Kapoor D; Kunte A; Chopde A; Puranik A; Dev ID; Parghane R; Basu S; Ramaswamy A; Ostwal V; Chaudhari VA; Bhandare MS; Shrikhande SV
    J Gastrointest Cancer; 2024 Sep; 55(3):1220-1228. PubMed ID: 38874852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New and emerging systemic therapy options for well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Scoville SD; Cloyd JM; Pawlik TM
    Expert Opin Pharmacother; 2020 Feb; 21(2):183-191. PubMed ID: 31760823
    [No Abstract]   [Full Text] [Related]  

  • 13. GEP-NETS update: Interventional radiology: role in the treatment of liver metastases from GEP-NETs.
    de Baere T; Deschamps F; Tselikas L; Ducreux M; Planchard D; Pearson E; Berdelou A; Leboulleux S; Elias D; Baudin E
    Eur J Endocrinol; 2015 Apr; 172(4):R151-66. PubMed ID: 25385817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk factors affecting prognosis in metachronous liver metastases from WHO classification G1 and G2 gastroenteropancreatic neuroendocrine tumors after initial R0 surgical resection.
    Lv Y; Han X; Xu XF; Ji Y; Zhou YH; Sun HC; Zhou J; Fan J; Lou WH; Huang C
    BMC Cancer; 2019 Apr; 19(1):335. PubMed ID: 30961559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of Metastatic GEPNETs.
    Limbach KE; Pommier RF
    Surg Oncol Clin N Am; 2020 Apr; 29(2):281-292. PubMed ID: 32151361
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HSP90 expression and early recurrence in gastroenteropancreatic neuroendocrine tumors: Potential for a novel therapeutic target.
    Gamboa AC; Ethun CG; Postlewait LM; Lopez-Aguiar AG; Zhelnin K; Krasinskas A; El-Rayes BF; Russell MC; Kooby DA; Staley CA; Cardona K; Maithel SK
    Surg Oncol; 2020 Dec; 35():460-465. PubMed ID: 33080545
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
    Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
    Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Peptide Receptor Radionuclide Therapy-Induced Hepatotoxicity in Patients With Metastatic Neuroendocrine Tumors.
    Riff BP; Yang YX; Soulen MC; Pryma DA; Bennett B; Wild D; Nicolas G; Teitelbaum UR; Metz DC
    Clin Nucl Med; 2015 Nov; 40(11):845-50. PubMed ID: 26284763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastroenteropancreatic neuroendocrine tumor microenvironment and related therapy].
    Ye C; Yuan CH; Li G; Zheng L; Xiu DR
    Zhonghua Wai Ke Za Zhi; 2019 Nov; 57(11):866-871. PubMed ID: 31694137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local treatment for focal progression in metastatic neuroendocrine tumors.
    Al-Toubah T; Partelli S; Cives M; Andreasi V; Silvestris F; Falconi M; Anaya DA; Strosberg J
    Endocr Relat Cancer; 2019 Apr; 26(4):405-409. PubMed ID: 30668527
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.